Articles by master

Saiba Animal Health AG enters into an Agreement with Boehringer Ingelheim

Pfäffikon (SZ) Switzerland 9th of December 2020 – Saiba Animal Health reported today that it has executed a contract with Boehringer Ingelheim. Saiba Animal Health AG announced Wednesday the commencement of an agreement with Boehringer Ingelheim, a global leader in animal health. The new partnership will further enable a core element of Saiba’s business strategy, …

Read More

HypoPet led consortium receives top ranking and funding from Eurostars Program for the research and development of a vaccine for African Swine Fever.

Zürich Switzerland 2nd of June 2020 – HypoPet AG today announced the ASF-INNOVAC consortium in which it is the lead SME was ranked 1st among 378 funding applications and will thus receive funding for 3 years to research and develop a vaccine against the African Swine Fever; one of the most serious infectious diseases affecting …

Read More

HypoPet Enters Into an Agreement with a Major Animal Health Company

Zürich Switzerland 2nd of October 2019 – HypoPet AG reported today that it has executed a contract with a top-tier global animal health company. HypoPet AG announced Wednesday the signing of an agreement with a major animal health company. The execution of this agreement is another important step in the companies publicly stated business plan, …

Read More

Key preclinical data for HypoPet’s cat allergy vaccine (HypoCat™ / VC001) published in leading allergy journal.

Zürich Switzerland 17th of April 2019 – HypoPet AG today announced the publication of important preclinical data for their cat allergy vaccine, HypoCat™. The data were published online 17th of April 2019 in an article entitled “Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. “in …

Read More

HypoPet AG today announced the publication of proof of principle data for a vaccine with the potential to translate into a novel therapy for osteoarthritic pain in companion animals

Zürich Switzerland 19th of March 2019 – HypoPet AG today announced the publication of proof of principle data for a vaccine with the potential to translate into a novel therapy for osteoarthritic pain in companion animals. The data were published online 12th of March 2019 in an article entitled “Active immunisation targeting nerve growth factor …

Read More

HypoPet to present at Animal Health Investment Forum London

HypoPet AG today announced that it has been selected as a finalist to present at the prestigious Animal Health Investment Europe Forum in February 2019. The Animal Health Innovation showcase provides an opportunity for the most exciting and innovative emerging animal health companies, selected by committee, to present their breakthrough innovations and business to investors …

Read More